Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Low incidence of GvHD with T-cell depleted allografts facilitates further treatments for post-transplantation relapse in AML and MDS

Bone Marrow Transplantation volume 51, pages 991–993 (2016)Cite this article

Subjects

Relapse remains a major cause of treatment failure following allogeneic hematopoietic stem cell transplant (HSCT) for patients with AML or myelodysplastic syndrome (MDS).1 Attempts at salvage following relapse include withdrawal of immunosuppression, chemotherapy, hypomethylating agents, donor lymphocyte infusions (DLIs) and a second HSCT.2 Success rates are variable and no standard of care exists.

GvHD is an important limiting factor for further treatment following relapse. Given the low incidence of GvHD with T-cell depleted (TCD)-HSCT,3, 4 we postulated that our patient population represents an important model for potential trial eligibility. We conducted a single-center retrospective analysis of patients who had disease recurrence following their TCD-HSCT for AML or MDS between January 2003 and November 2011 at Memorial Sloan Kettering Cancer Center (MSKCC; New York, NY, USA) to determine their hypothetical eligibility for post-HSCT relapse management trials from clinicaltrails.gov. This review was performed under a waiver of authorization approved by the Institutional Review Board of MSKCC.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. van den Brink MR, Porter DL, Giralt S, Lu SX, Jenq RR, Hanash A et al. Relapse after allogeneic hematopoietic cell therapy. Biol Blood Marrow Transplant 2010; 16: S138–S145.

    Article  PubMed  Google Scholar 

  2. Pollyea DA, Artz AS, Stock W, Daugherty C, Godley L, Odenike OM et al. Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2007; 40: 1027–1032.

    Article  CAS  PubMed  Google Scholar 

  3. Papadopoulos EB, Carabasi MH, Castro-Malaspina H, Childs BH, Mackinnon S, Boulad F et al. T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease. Blood 1998; 91: 1083–1090.

    CAS  PubMed  Google Scholar 

  4. Jakubowski AA, Small TN, Kernan NA, Castro-Malaspina H, Collins N, Koehne G et al. T cell-depleted unrelated donor stem cell transplantation provides favorable disease-free survival for adults with hematologic malignancies. Biol Blood Marrow Transplant 2011; 17: 1335–1342.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Devine SM, Carter S, Soiffer RJ, Pasquini MC, Hari PN, Stein A et al. Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the blood and marrow transplant clinical trials network protocol 0303. Biol Blood Marrow Transplant 2011; 17: 1343–1351.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Castro-Malaspina H, Jabubowski AA, Papadopoulos EB, Boulad F, Young JW, Kernan NA et al. Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings. Biol Blood Marrow Transplant 2008; 14: 458–468.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Hosing C, Saliba RM, Shahjahan M, Estey EH, Couriel D, Giralt S et al. Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemia. Bone Marrow Transplant 2005; 36: 157–162.

    Article  CAS  PubMed  Google Scholar 

  8. Krishnamurthy P, Potter VT, Barber LD, Kulasekararaj AG, Lim ZY, Pearce RM et al. Outcome of donor lymphocyte infusion after T cell-depleted allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromes. Biol Blood Marrow Transplant 2013; 19: 562–568.

    Article  PubMed  Google Scholar 

  9. O’Reilly RJ, Dao T, Koehne G, Scheinberg D, Doubrovina E . Adoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation. Semin Immunol 2010; 22: 162–172.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Oran B, Giralt S, Couriel D, Hosing C, Shpall EJ, de Meis E et al. Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation. Leukemia 2007; 21: 2540–2544.

    Article  CAS  PubMed  Google Scholar 

  11. Schmid C, Labopin M, Nagler A, Niederwieser D, Castagna L, Tabrizi R et al. Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. Blood 2012; 119: 1599–1606.

    Article  CAS  PubMed  Google Scholar 

  12. Levine JE, Braun T, Penza SL, Beatty P, Cornetta K, Martino R et al. Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. J Clin Oncol 2002; 20: 405–412.

    Article  CAS  PubMed  Google Scholar 

  13. Warlick ED, DeFor T, Blazar BR, Burns L, Verneris MR, Ustun C et al. Successful remission rates and survival after lymphodepleting chemotherapy and donor lymphocyte infusion for relapsed hematologic malignancies postallogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012; 18: 480–486.

    Article  PubMed  Google Scholar 

  14. Devillier R, Crocchiolo R, Etienne A, Prebet T, Charbonnier A, Furst S et al. Outcome of relapse after allogeneic stem cell transplant in patients with acute myeloid leukemia. Leuk Lymphoma 2013; 54: 1228–1234.

    Article  PubMed  Google Scholar 

  15. Bejanyan N, Weisdorf DJ, Logan BR, Wang HL, Devine SM, de Lima M et al. Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study. Biol Blood Marrow Transplant 2015; 21: 454–459.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    P B Dahi, E Morawa, M-A Perales, M Maloy, H Castro-Malaspina, E B Papadopoulos, A A Jakubowski & S A Giralt

  2. Weill Cornell Medical College, New York, NY, USA

    P B Dahi, E Morawa, M-A Perales, H Castro-Malaspina, R J O'Reilly, E B Papadopoulos, A A Jakubowski & S A Giralt

  3. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    E C Zabor & S M Devlin

  4. Department of Pediatrics, Pediatric Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    R J O'Reilly

Authors
  1. P B Dahi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E Morawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M-A Perales
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E C Zabor
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S M Devlin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M Maloy
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. H Castro-Malaspina
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. R J O'Reilly
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. E B Papadopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. A A Jakubowski
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. S A Giralt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P B Dahi.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Author contributions

PBD and EM designed the study, collected, analyzed and interpreted the data, and wrote the manuscript; ECZ and SMD performed the statistics and wrote the manuscript; MAP, MM, HCM, RJO, EBP and AAJ wrote the manuscript; and SAG designed the study and wrote the manuscript.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dahi, P., Morawa, E., Perales, MA. et al. Low incidence of GvHD with T-cell depleted allografts facilitates further treatments for post-transplantation relapse in AML and MDS. Bone Marrow Transplant 51, 991–993 (2016). https://doi.org/10.1038/bmt.2016.23

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2016.23

This article is cited by

Search

Advanced search

Quick links